SOURCE: Actinium Pharmaceuticals
Scientific Advisory Board Member Dr. Sergio Giralt to Lead Bone Marrow Transplant Educational Sessio
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM)
("Actinium" or "the Company"), a biopharmaceutical Company developing
innovative targeted payload immunotherapeutics for the treatment of
advanced cancers, is partnering with the Aplastic Anemia & MDS
International Foundation, a leading non-profit health organization, to
present educational forums to patients and their families on bone marrow
transplant, MDS, aplastic anemia and PNH.
The next AA&MDSIF
Patient and Family Conference will take place in Cleveland, Ohio at the
Cleveland Airport Marriott on Saturday May 2, 8:30am-5:00pm.
Sergio
Giralt, MD, Chief of Adult Bone Marrow Transplant Service at Memorial
Sloan Kettering Cancer Center, and Actinium Scientific Advisory Board
Member, will present "Understanding BMT, Before and During" and "Bone
Marrow Transplant: Managing Post BMT Health and Support" as part of the
bone marrow transplant educational track. Additional conferences will
take place throughout 2015 in San Francisco, Boston, Chicago and Tampa
with a variety of distinguished speakers.
About Bone Marrow TransplantBone
marrow transplants (BMT) are used to treat a variety of hematologic
conditions including leukemia and MDS. BMT involves first clearing a
patient's body of his or her own immune cells and then transplanting
bone marrow, the source of all blood- and immune-forming cells, from a
tissue-matched donor. The new cells, which are free of cancer,
repopulate the patient's bone marrow and eventually give rise to a
functioning set of blood and immune cells, providing a lifelong cure.
BMT offers the chance of a "curative" outcome (2+ year survival), and
therefore can play a central role in the treatment of acute myeloid
leukemia (AML). The impact of BMT on AML continues to increase with AML
being the most common and fastest growing indication for allogeneic BMT,
comprising 25% to 30% of all BMT recipients. There are currently over
100,000 BMT survivors across all indications and this number is expected
to increase to 250,000 by 2020 and 500,000 by 2030, with 25% of them
over age 60.
About AAMDS International FoundationThe Aplastic Anemia & MDS
International Foundation (AA&MDSIF) is the world's leading
nonprofit health organization dedicated to supporting patients and
families living with aplastic anemia, myelodysplastic syndromes (MDS),
paroxysmal nocturnal hemoglobinuria (PNH), acute myeloid leukemia (AML) and related bone marrow failure
diseases. AA&MDSIF provides answers, support and hope to thousands
of patients and their families around the world. It is a
patient-focused, patient-centered organization, serving patients and
families throughout the three phases of bone marrow failure diseases:
the life changing phase of diagnosis, the life threatening phase of
treatment and the lifelong phase of living with disease.
About Iomab-B™
Iomab-B™ is being developed to prepare patients for
hematopoietic stem cell transplantation (HSCT) and will enter a single,
pivotal Phase 3 clinical study in relapsed/refractory AML. Iomab-B is a
radioimmunoconjugate consisting of BC8, a novel murine monoclonal
antibody, and iodine-131 radioisotope. BC8 has been developed by Fred
Hutchinson Cancer Research Center to target CD45, a pan-leukocytic
antigen widely expressed on white blood cells. This antigen makes BC8
potentially useful in targeting white blood cells in preparation for
hematopoietic stem cell transplantation in a number of blood cancer
indications, including acute myeloid leukemia (AML).
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com)
is a New York-based biopharmaceutical company developing innovative
targeted payload immunotherapeutics for the treatment of advanced
cancers. Actinium's targeted radiotherapy products are based on its
proprietary delivery platform for the therapeutic utilization of
alpha-emitting actinium-225 and bismuth-213 and certain beta emitting
radiopharmaceuticals in conjunction with monoclonal antibodies. The
Company's lead radiopharmaceutical product candidate Iomab-B is designed
to be used, upon approval, in preparing patients for hematopoietic stem
cell transplant, commonly referred to as bone marrow transplant. The
Company plans to conduct a single, pivotal, multicenter Phase 3 clinical
study of Iomab-B in refractory and relapsed AML patients over the age
of 55 with a primary endpoint of durable complete remission. The
Company's second product candidate, Actimab-A, is continuing its
clinical development in a Phase 1/2 trial for newly diagnosed AML
patients over the age of 60 in a single-arm multicenter trial.
No comments:
Post a Comment